NCT03605082bepranemabUP0047tauopathiesUP0065
…cs (PD) of bepranemab.Methods UP0047 ( NCT03464227) and UP0065 (NCT03605082) were phase 1, double-blind, placebo-controlled, single-dose, d…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT03605082 ×
NCT03605082
This funder is selected. Its supporting articles are shown below.